Gerald L. Ray & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Gerald L. Ray & Associates’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$25M	Sell	55,899 -281	-0.5%	-$134K	3.12%	3
2017 Q2	$27.6M	Sell	56,180 -175	-0.3%	-$76.6K	3.56%	3
2017 Q1	$21.8M	Sell	56,355 -943	-2%	-$350K	2.99%	4
2016 Q4	$21M	Sell	57,298 -786	-1%	-$299K	3.05%	3
2016 Q3	$23.4M	Sell	58,084 -139	-0.2%	-$55.8K	3.5%	3
2016 Q2	$20.3M	Sell	58,223 -750	-1%	-$289K	3.25%	3
2016 Q1	$21.3M	Sell	58,973 -2,730	-4%	-$1.12M	3.44%	3
2015 Q4	$33.5M	Sell	61,703 -873	-1%	-$473K	5.29%	2
2015 Q3	$29.1M	Sell	62,576 -1,140	-2%	-$612K	4.85%	2
2015 Q2	$32.5M	Sell	63,716 -1,160	-2%	-$566K	4.95%	1
2015 Q1	$29.3M	Sell	64,876 -1,255	-2%	-$532K	4.41%	3
2014 Q4	$27.1M	Sell	66,131 -304	-0.5%	-$120K	4.17%	3
2014 Q3	$24M	Sell	66,435 -775	-1%	-$260K	3.9%	3
2014 Q2	$19M	Sell	67,210 -660	-1%	-$196K	3.24%	3
2014 Q1	$20.4M	Sell	67,870 -515	-0.8%	-$159K	3.69%	2
2013 Q4	$18.8M	Sell	68,385 -1,255	-2%	-$361K	3.55%	2
2013 Q3	$21.8M	Sell	69,640 -850	-1%	-$224K	4.51%	1
2013 Q2	$15.9M	Buy	+70,490	New	+$16.4M	3.55%	1

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Gerald L. Ray & Associates's REGN Position: Q3 2017 in Review

Gerald L. Ray & Associates reduced its Regeneron Pharmaceuticals (REGN) stake by 0.5% in Q3 2017, selling an estimated $134K and leaving 55,899 shares worth $25M. The position accounts for 3.12% of the portfolio, ranked #3.

Gerald L. Ray & Associates first reported a position in REGN in Q2 2013 and has held it in 18 quarters since. The position peaked at $33.5M in Q4 2015. 605 funds tracked by Wall St. Rank hold REGN as of Q3 2017.

Gerald L. Ray & Associates held 55,899 shares of Regeneron Pharmaceuticals worth $25M as of Q3 2017.
Gerald L. Ray & Associates sold 281 Regeneron Pharmaceuticals shares in Q3 2017, an estimated $134K.
Regeneron Pharmaceuticals made up 3.12% of Gerald L. Ray & Associates's portfolio in Q3 2017, its #3 holding.
Gerald L. Ray & Associates first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 18 quarters since.
Gerald L. Ray & Associates's Regeneron Pharmaceuticals position peaked at $33.5M in Q4 2015.
605 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2017.

Based on Gerald L. Ray & Associates's 13F filing for Q3 2017, filed 31 Oct 2017.